News https://www.benzinga.com/views/taxonomy/term/57 en McEwen Mining Reports Q2 2019 Production Results https://www.benzinga.com/pressreleases/19/07/g14086270/mcewen-mining-reports-q2-2019-production-results <link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /> <p align="justify">TORONTO, July 17, 2019 (GLOBE NEWSWIRE) -- <strong>McEwen Mining Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUX#NYSE" rel="nofollow">MUX</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MUX#TSX" rel="nofollow">MUX</a>)</strong> reports consolidated production for <strong>Q2</strong> <strong>2019</strong> of <strong>36,216</strong> gold ounces and <strong>850,525</strong> silver ounces, or <strong>45,881</strong> gold equivalent ounces<sup>(1)</sup> ("GEOs") using the average gold:silver price ratio during Q2 of <strong>88:1</strong>. Our San José and El Gallo mines, which accounted for 62% our total gold and silver production in Q2<strong>, </strong>exceeded our targets. Our other two operations, the Gold Bar and Black Fox mines, performed better than in Q1, but below our forecast. Looking ahead, our production guidance for the year 2019 has been reduced by 6% for gold and is unchanged for silver. On a gold equivalent basis, silver is forecast to represent 20% of our 2019 consolidated production of 190,000 GEOs.</p> <table class="gnw_table_border_collapse hugin" style="width:100%; border-collapse:collapse !important;"> <tr> <td class="gnw_align_center hugin gnw_vertical_align_middle" colspan="8"> </td> </tr> <tr> <td class="gnw_align_center hugin gnw_vertical_align_middle" colspan="8"><strong>Consolidated Production Summary</strong></td> </tr> <tr> <td class="gnw_align_center hugin gnw_vertical_align_middle" colspan="8"> </td> </tr> <tr> <td class="gnw_border_top_solid gnw_align_center hugin gnw_vertical_align_middle"><em> </em></td> <td class="gnw_border_top_solid gnw_border_right_solid gnw_border_bottom_solid gnw_align_center hugin gnw_vertical_align_middle" colspan="2">Q1</td> <td class="gnw_border_top_solid gnw_border_right_solid gnw_border_bottom_solid gnw_align_center hugin gnw_vertical_align_middle" colspan="2">Q2</td> <td class="gnw_border_top_solid gnw_border_bottom_solid gnw_align_center hugin gnw_vertical_align_middle" colspan="3">Full Year</td> </tr> <tr> <td class="gnw_border_bottom_solid gnw_align_center hugin gnw_vertical_align_middle" style="max-width:15%; width:15%; min-width:15%;"> </td> <td class="gnw_border_bottom_solid gnw_align_center hugin gnw_vertical_align_middle" style="max-width:14%; width:14%; min-width:14%;">2018</td> <td class="gnw_border_right_solid gnw_border_bottom_solid gnw_align_center hugin gnw_vertical_align_middle" style="max-width:14%; width:14%; min-width:14%;"><strong>2019</strong></td> <td class="gnw_border_right_solid gnw_border_bottom_solid gnw_align_center hugin gnw_vertical_align_middle" style="max-width:14%; width:14%; min-width:14%;">2018</td> <td class="gnw_border_right_solid gnw_border_bottom_solid gnw_align_center hugin gnw_vertical_align_middle" style="max-width:14%; width:14%; min-width:14%;"><strong>2019</strong></td> <td class="gnw_border_right_solid gnw_border_bottom_solid gnw_align_center hugin gnw_vertical_align_middle" style="max-width:14%; width:14%; min-width:14%;">2018</td> <td class="gnw_border_bottom_solid gnw_align_center hugin gnw_vertical_align_middle" colspan="2" style="max-width:15%; width:15%; min-width:15%;"><strong>2019</strong><br /><strong>Guidance</strong></td> </tr> <tr> <td class="gnw_label_i10 hugin gnw_vertical_align_middle">Gold (oz)</td> <td class="gnw_align_right hugin gnw_vertical_align_middle">35,069 </td> <td class="gnw_border_right_solid gnw_align_right hugin gnw_vertical_align_middle"><strong>26,938 </strong></td> <td class="gnw_border_right_solid gnw_align_right hugin gnw_vertical_align_middle">36,959 </td> <td class="gnw_border_right_solid gnw_align_right hugin gnw_vertical_align_middle"><strong>36,216 </strong></td> <td class="gnw_border_right_solid gnw_align_right hugin gnw_vertical_align_middle">135,203 </td> <td class="gnw_align_right hugin gnw_vertical_align_middle" colspan="2"><strong>152,000 </strong></td> </tr> <tr> <td class="gnw_label_i10 hugin gnw_vertical_align_middle">Silver (oz)</td> <td class="gnw_align_right hugin gnw_vertical_align_middle">695,651 </td> <td class="gnw_border_right_solid gnw_align_right hugin gnw_vertical_align_middle"><strong>703,219 </strong></td> <td class="gnw_border_right_solid gnw_align_right hugin gnw_vertical_align_middle">772,432 </td> <td class="gnw_border_right_solid gnw_align_right hugin gnw_vertical_align_middle"><strong>850,525 </strong></td> <td class="gnw_border_right_solid gnw_align_right hugin gnw_vertical_align_middle">3,032,694 </td> <td class="gnw_align_right hugin gnw_vertical_align_middle" colspan="2"><strong>3,225,000 </strong></td> </tr> <tr> <td class="gnw_border_bottom_solid gnw_label_i10 hugin gnw_vertical_align_middle">GEOs<sup>(1)</sup></td> <td class="gnw_border_bottom_solid gnw_align_right hugin gnw_vertical_align_middle">44,344 </td> <td class="gnw_border_right_solid gnw_border_bottom_solid gnw_align_right hugin gnw_vertical_align_middle"><strong>36,315 </strong></td> <td class="gnw_border_right_solid gnw_border_bottom_solid gnw_align_right hugin gnw_vertical_align_middle">47,258 </td> <td class="gnw_border_right_solid gnw_border_bottom_solid gnw_align_right hugin gnw_vertical_align_middle"><strong>45,881 </strong></td> <td class="gnw_border_right_solid gnw_border_bottom_solid gnw_align_right hugin gnw_vertical_align_middle">175,640 </td> <td class="gnw_border_bottom_solid gnw_align_right hugin gnw_vertical_align_middle" colspan="2"><strong>190,000 </strong></td> </tr> <tr> <td class="gnw_align_justify hugin gnw_vertical_align_middle" colspan="8"><strong>(1) </strong>&#39;Gold Equivalent Ounces&#39; are calculated based on a 75:1 gold to silver price ratio for periods up to and including Q1 2019, and 88:1 for Q2 2019. Going forward McEwen has adopted a variable gold:silver ratio for reporting that approximates the average during each fiscal quarter. 2019 GEO Guidance has been restated at an 85:1 ratio, resulting in a decrease of 5,000 GEOs.</td> </tr> <tr> <td class="gnw_label_i15 gnw_align_justify hugin gnw_vertical_align_middle" colspan="8"> </td> </tr> </table> <p align="justify">Rob McEwen, Chairman and Chief Owner commented: <strong><em>"The big events in Q2 were achieving commercial production at Gold Bar in late May and the high-grade exploration results from the Black Fox properties. Production results in the quarter were mixed. San José and El Gallo, which accounted for 62% of our Q2 production, performed well this quarter. At Gold Bar and Black Fox, we have had our head down and were pushing hard all quarter long. While both mines delivered better production in Q2 than in Q1, we didn&#039;t achieve our forecast numbers. As a result, we have reduced our 2019 production guidance for gold by 6%."</em></strong><br /></p> <p align="justify"><strong><u>Gold Bar Mine, Nevada</u></strong><strong><u> (100%)</u></strong></p> <p align="justify">Commercial production was achieved at Gold Bar on May 23, 2019. Gold Bar produced <strong>7,940</strong> gold ounces in <strong>Q2</strong>. The ramp-up to full production is progressing but the delays in Q1 adversely impacted our gold production in Q2 and our forecast for 2019.</p> <p align="justify">In essence, less ...</p><p><a href=https://www.benzinga.com/pressreleases/19/07/g14086270/mcewen-mining-reports-q2-2019-production-results alt=McEwen Mining Reports Q2 2019 Production Results>Full story available on Benzinga.com</a></p> Earnings MUX News TSX:MUX Markets Press Releases General MUX TSX:MUX News Earnings Markets Press Releases General Benzinga Wed, 17 Jul 2019 10:15:00 +0000 Globe Newswire 14086270 at https://www.benzinga.com Immuron to Host Investor Webinar on July 18 to Provide Update on Recent Developments https://www.benzinga.com/pressreleases/19/07/g14086177/immuron-to-host-investor-webinar-on-july-18-to-provide-update-on-recent-developments <link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /> <p align="justify">MELBOURNE, Australia, July 17, 2019 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRN#NASDAQ" rel="nofollow">IMRN</a>), an Australian biopharmaceutical company, announced today that it will participate in an investor webinar and Q&amp;A session on Thursday, July 18, 2019, at 10:30 a.m. EST (US time), hosted by RedChip Companies.<br /></p> <p align="justify">The webinar will feature a presentation by CEO Gary S. Jacob, Ph.D who will discuss recent achievements and upcoming milestones related to the company&#039;s development pipeline.</p> <p align="justify">To register for the free webinar, please visit:  <a href="https://www.globenewswire.com/Tracker?data=lN2DSIO80W7FkmhxhUss-V7FVu6CT6TDI3t-HJTH8i7SPp2PjIHsXCUPBlUoIG9JZlgogg_nMirj8u9bMdhdKDhElIDzC8GPrd4zg843nXnSwYP5AhvzA3lhFBGowUqv7szphKDn95MX_SKAtHcDjep4TLovwv6yzHvRpkkIzZA=" rel="nofollow" target="_blank" rel="nofollow"><u>https://www.redchip.com/corporate/webinar_register/43</u></a></p> <p align="justify"><strong>ABOUT IMMURON:<br /></strong>Immuron Limited ((ASX: IMC, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRN#NASDAQ" rel="nofollow">IMRN</a>), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. Immuron has a novel and safe technology platform with one commercial asset generating revenue. In Australia, Travelan® is a listed medicine on the Australian Register of Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travellers&#039; Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan® is a licenced natural ...</p><p><a href=https://www.benzinga.com/pressreleases/19/07/g14086177/immuron-to-host-investor-webinar-on-july-18-to-provide-update-on-recent-developments alt=Immuron to Host Investor Webinar on July 18 to Provide Update on Recent Developments>Full story available on Benzinga.com</a></p> IMRN News Press Releases IMRN News Press Releases Benzinga Wed, 17 Jul 2019 10:00:00 +0000 Globe Newswire 14086177 at https://www.benzinga.com US Ecology Announces Schedule for its Second Quarter 2019 Earnings Release and Conference Call https://www.benzinga.com/pressreleases/19/07/g14086172/us-ecology-announces-schedule-for-its-second-quarter-2019-earnings-release-and-conference-call <link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /> <p align="justify">BOISE, Idaho, July 17, 2019 (GLOBE NEWSWIRE) -- US Ecology, Inc. (the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECOL#NASDAQ" rel="nofollow">ECOL</a>) today announced that it will release financial results for the second quarter ended June 30, 2019 on Thursday, August 1, 2019, after the close of the market.<br /></p> <p align="justify">Management will conduct an investor conference call on Friday, August 2, 2019 at 10:00 a.m. Eastern Time (8:00 a.m. Mountain Time) to discuss these results. Questions will be invited after management&#039;s presentation. Interested parties can access the conference call ...</p><p><a href=https://www.benzinga.com/pressreleases/19/07/g14086172/us-ecology-announces-schedule-for-its-second-quarter-2019-earnings-release-and-conference-call alt=US Ecology Announces Schedule for its Second Quarter 2019 Earnings Release and Conference Call>Full story available on Benzinga.com</a></p> Earnings ECOL News Markets Press Releases ECOL US91732J1025 News Earnings Markets Press Releases Benzinga Wed, 17 Jul 2019 10:00:00 +0000 Globe Newswire 14086172 at https://www.benzinga.com 58 Biggest Movers From Yesterday https://www.benzinga.com/news/19/07/14086006/58-biggest-movers-from-yesterday <h3><strong>Gainers</strong></h3> <ul> <li><strong>IMMURON LTD/S ADR</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/imrn#NASDAQ">IMRN</a>) shares jumped 46.8% to close at $4.30 on Tuesday after the company reported FY19 North American revenues up 52% from last year.</li> <li><strong>Blue Apron Holdings, Inc. </strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aprn#NYSE">APRN</a>) gained 35.5% to close at $10.38. Blue Apron on Tuesday announced a partnership with plant-based foodmaker <strong>Beyond Meat Inc</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bynd#NASDAQ">BYND</a>). As part of the new partnership, Blue Apron customers can now order meal kits for delivery in August that will include Beyond Meat&#39;s plant-based proteins. The first meal kit will consist of caramelized onion and cheddar burgers with garlic green beans. The second meal will include jalapeno and goat cheese burgers with corn on the cob.</li> <li><strong>Bio-Path Holdings, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bpth#NASDAQ">BPTH</a>) surged 33.1% to close at $17.17. H.C. Wainwright initiated coverage on Bio-Path with a Buy rating and a $28 price target.</li> <li><strong>Taronis Technologies Inc</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trnx#NASDAQ">TRNX</a>) rose 28.6% to close at $0.45 after the company announced it will spin off its Taronis Fuels subsidiary.</li> <li><strong>GAIN Capital Holdings, Inc. </strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gcap#NYSE">GCAP</a>) shares rose 24.3% to close at $5.01.</li> <li><strong>Cancer Genetics, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cgix#NASDAQ">CGIX</a>) rose 21.5% to close at $0.2066 after reporting Interpace Diagnostics will purchase the company&#39;s Biopharma services unit.</li> <li><strong>Therapix Biosciences Ltd. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trpx#NASDAQ">TRPX</a>) gained 17.6% to close at $2.7750.</li> <li><strong>Interpace Diagnostics Group, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/idxg#NASDAQ">IDXG</a>) climbed 16.8% to close at $0.8150. Interpace Diagnostics reported the purchase of Biopharma Services unit of Cancer Genetics. Ampersand Capital Partners agreed to invest $27 million in Interpace Diagnostics in two tranches of newly issued convertible preferred stock.</li> <li><strong>AVROBIO, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avro#NASDAQ">AVRO</a>) rose 16.7% to close at $19.16.</li> <li><strong>Spartan Motors, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/spar#NASDAQ">SPAR</a>) gained 16.3% to close at $11.52 after the company announced it received a 2,237-unit walk-in-van order from North America&#39;s leading online e-commerce and fulfillment company.</li> <li><strong>Unum Therapeutics Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/umrx#NASDAQ">UMRX</a>) rose 15.4% to close at $2.63.</li> <li><strong>Curis, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cris#NASDAQ">CRIS</a>) shares climbed 15% to close at $2.83.</li> <li><strong>Lonestar Resources US Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lone#NASDAQ">LONE</a>) gained 14.7% to close at $2.66.</li> <li><strong>China Customer Relations Centers, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ccrc#NASDAQ">CCRC</a>) rose 14.6% to close at $10.94.</li> <li><strong>Fortuna Silver Mines Inc. </strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fsm#NYSE">FSM</a>) shares ...</li></ul><p><a href=https://www.benzinga.com/news/19/07/14086006/58-biggest-movers-from-yesterday alt=58 Biggest Movers From Yesterday>Full story available on Benzinga.com</a></p> ABUS ACER AKS ALTM APRN ATRA AVRO BPTH BYND CCRC CDNA CEI CELH CGIX CIDM CLDC CRIS CRVS CSBR CTST DNJR DPZ ERII EYEN FCAU FDS FRAN FSM GCAP GNMX IDEX IDXG IMRN ISSC JBHT KIN LEA LKCO LONE Losers MGEN MLNT Movers From Tuesday Movers From Yesterday News NTEC PERI PHUN PIR PT QTT REKR SCPH SOLY SPAR TNXP Top Gainers TRNX TRPX TRQ UMRX UUU WTFC XNET Yesterday's Gainers Movers & Shakers Pre-Market Outlook Markets Movers Trading Ideas General UUU US9138213023 CIDM US1724071089 CRIS US2312691015 ERII US29270J1007 ISSC US45769N1054 JBHT US4456581077 SPAR US8468191007 WTFC US97650W1080 AKS US0015471081 DPZ US25754A2015 FDS US3030751057 LEA US5218652049 PIR US7202791080 PT US7372731023 CEI BPTH US09057N1028 GCAP US36268W1009 CELH US15118V2079 TRNX NL0009693746 FRAN SOLY TNXP PERI FSM PHUN CSBR ALTM TRQ CGIX KIN ATRA CDNA XNET FCAU CCRC NTEC ABUS CRVS IDXG CLDC LONE TRPX GNMX MGEN IMRN APRN ACER MLNT SCPH EYEN DNJR UMRX AVRO QTT LKCO IDEX BYND CTST REKR News Movers & Shakers Pre-Market Outlook Markets Movers Trading Ideas General Benzinga Wed, 17 Jul 2019 08:59:05 +0000 Lisa Levin 14086006 at https://www.benzinga.com 10 Stocks To Watch For July 17, 2019 https://www.benzinga.com/news/earnings/19/07/14085972/10-stocks-to-watch-for-july-17-2019 <p>Some of the stocks that may grab investor focus today are:</p> <ul> <li>Wall Street expects <strong>Bank of America Corporation</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bac#NYSE">BAC</a>) to report quarterly earnings at $0.71 per share on revenue of $23.23 billion before the opening bell. Bank of America shares rose 0.1% to $29.02 in pre-market trading.</li> <li>Analysts expect <strong>Netflix, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nflx#NASDAQ">NFLX</a>) to post quarterly earnings at $0.56 per share on revenue of $4.93 billion after the closing bell. Netflix shares rose 0.4% to $367.37 in pre-market trading.</li> <li><strong>CSX Corporation</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/csx#NASDAQ">CSX</a>) reported weaker-than-expected results for its second quarter on Tuesday. CSX shares dipped 6.3% to $74.55 in the pre-market trading session.</li> <li>Analysts are expecting <strong> U.S. Bancorp </strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/usb#NYSE">USB</a>) to have ...</li></ul><p><a href=https://www.benzinga.com/news/earnings/19/07/14085972/10-stocks-to-watch-for-july-17-2019 alt=10 Stocks To Watch For July 17, 2019>Full story available on Benzinga.com</a></p> ABT BAC CSX CTAS Earnings EBAY IBM News NFLX PNC Stocks To Watch Stocks to Watch UAL USB Pre-Market Outlook Markets Trading Ideas CTAS US1729081059 EBAY US2786421030 NFLX US64110L1061 ABT US0028241000 BAC US0605051046 CSX US1264081035 IBM US4592001014 PNC US6934751057 USB US9029733048 UAL US9100471096 News Earnings Pre-Market Outlook Markets Trading Ideas Benzinga Wed, 17 Jul 2019 08:28:31 +0000 Lisa Levin 14085972 at https://www.benzinga.com Earnings Scheduled For July 17, 2019 https://www.benzinga.com/news/earnings/19/07/14085957/earnings-scheduled-for-july-17-2019 <h3>Companies Reporting Before The Bell</h3> <ul> <li><strong>Abbott Laboratories</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/abt#NYSE">ABT</a>) is expected to report quarterly earnings at $0.80 per share on revenue of $8.00 billion.</li> <li><strong>Bank of America Corporation</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bac#NYSE">BAC</a>) is estimated to report quarterly earnings at $0.71 per share on revenue of $23.23 billion.</li> <li><strong>U.S. Bancorp </strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/usb#NYSE">USB</a>) is projected to report quarterly earnings at $1.07 per share on revenue of $5.73 billion.</li> <li><strong>Omnicom Group Inc. </strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/omc#NYSE">OMC</a>) is estimated to report quarterly earnings at $1.61 per share on revenue of $3.72 billion.</li> <li><strong>The PNC Financial Services Group, Inc. </strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pnc#NYSE">PNC</a>) is projected to report quarterly earnings at $2.82 per share on revenue of $4.41 billion.</li> <li><strong>Textron Inc. </strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/txt#NYSE">TXT</a>) is expected to report quarterly earnings at $0.86 per share on revenue of $3.44 billion.</li> <li><strong>Wipro Limited</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wit#NYSE">WIT</a>) is projected to report quarterly earnings at $0.06 per share on revenue of $2.12 billion.</li> <li><strong>ASML Holding N.V. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/asml#NASDAQ">ASML</a>) is expected to report quarterly earnings at $1.75 per share on revenue of $2.76 billion.</li> <li><strong>The Bank of New York ...</strong></li></ul><p><a href=https://www.benzinga.com/news/earnings/19/07/14085957/earnings-scheduled-for-july-17-2019 alt=Earnings Scheduled For July 17, 2019>Full story available on Benzinga.com</a></p> AA ABT ADTN ASML BAC BK BXS CCI CCK CMA Earnings Earnings Scheduled EBAY ERIC IBM KMI News NFLX OMC PGR PLXS PNC RLI SLG TCBI TXT UMPQ URI USB WIT Pre-Market Outlook Markets ADTN US00738A1060 ASML USN070591862 EBAY US2786421030 ERIC US2948216088 NFLX US64110L1061 PLXS US7291321005 TCBI US88224Q1076 UMPQ US9042141039 AA US0138171014 ABT US0028241000 BAC US0605051046 BK US0640581007 BXS US0596921033 CCI US2282271046 CCK US2283681060 CMA US2003401070 IBM US4592001014 OMC US6819191064 PGR US7433151039 PNC US6934751057 RLI US7496071074 SLG US78440X1019 TXT US8832031012 URI US9113631090 USB US9029733048 WIT US97651M1099 KMI US49456B1017 News Earnings Pre-Market Outlook Markets Benzinga Wed, 17 Jul 2019 08:16:15 +0000 Lisa Levin 14085957 at https://www.benzinga.com Economic Data Scheduled For Wednesday https://www.benzinga.com/news/19/07/14085924/economic-data-scheduled-for-wednesday <ul> <li>The MBA&#39;s index of mortgage application activity for the latest week is schedule for release at 7:00 a.m. ET.</li> <li>Data on housing starts and permits for June will be released ...</li></ul><p><a href=https://www.benzinga.com/news/19/07/14085924/economic-data-scheduled-for-wednesday alt=Economic Data Scheduled For Wednesday>Full story available on Benzinga.com</a></p> Economic Data News Economics Pre-Market Outlook Markets News Economics Pre-Market Outlook Markets Benzinga Wed, 17 Jul 2019 07:59:01 +0000 Lisa Levin 14085924 at https://www.benzinga.com Nicox: Second Quarter 2019 Business Update and Financial Highlights https://www.benzinga.com/pressreleases/19/07/g14085677/nicox-second-quarter-2019-business-update-and-financial-highlights <link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /> <table class="gnw_table_border_collapse hugin" style="margin-left:9pt; width:472.7pt; border-collapse:collapse !important;"> <tr> <td class="gnw_border_bottom_solid hugin gnw_vertical_align_top" colspan="3" style="width:630.27px;"><strong>Press Release</strong></td> </tr> <tr> <td class="gnw_border_bottom_solid gnw_align_justify hugin gnw_vertical_align_top" colspan="3" style="width:630.27px;">Nicox: Second Quarter 2019 Business Update and Financial Highlights</td> </tr> <tr> <td class="hugin gnw_vertical_align_top" colspan="3" style="width:630.27px;"><br /><br /><br /> <ul type="disc"> <li><strong>Enrollment completed in the NCX 470 Phase 2 clinical trial in patients with glaucoma and ocular hypertension with results expected in early Q4 of this year</strong><br /> </li> <li><strong>Q2 2019 net revenue, including licensing payments, of €5.2 million</strong></li> </ul> <p> <br /><br /> July 17, 2019– release at 7:30 am CET <br />Sophia Antipolis, France<br /><br /> <strong> </strong><br /><br /> <strong>Nicox SA</strong> (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today provided Q2 2019 operational highlights, revenue and cash position for Nicox and its subsidiaries (the "Nicox Group"), as well as key upcoming milestones.<br /><br /> <strong>Michele Garufi, Chairman and Chief Executive Officer of Nicox</strong><em>, </em>said<em>, "Completion of enrollment in the NCX 470 glaucoma trial was a major step in delivering on the strategy for Nicox and keeps us on track for reporting the results of this study in early Q4, along with those of the NCX 4251 blepharitis trial later in the quarter.  In preparation for the next steps with these two programs, we are strengthening the development function and have hired Dr. José Boyer into the new position of Vice President of Clinical Development.  Our strategic business development activities continue to be fruitful with the recent NCX 4251 licensing deal in China consolidating our partnership there with Ocumension and we are expanding our global licensing efforts outside the US and Europe in order to optimize the value of our portfolio."</em><br /><br /> <strong>Key Upcoming Milestones</strong><br /><br /><br /> <ul type="disc"> <li style="text-align:justify;"><strong>NCX 470 Phase 2 results:</strong> Following completion of enrollment, top-line data from the first efficacy Phase 2 clinical trial for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension expected in early Q4 of this year.</li> <li style="text-align:justify;"><strong>NCX 4251 Phase 2 results:</strong> Trial in patients with acute exacerbations of blepharitis continuing on track for top-line data expected in Q4 of this year.</li> <li style="text-align:justify;"><strong>ZERVIATE partnering outside of the U.S.</strong>: Multiple discussions ongoing for potential new licensing agreements in significant markets.</li> <li style="text-align:justify;"><strong>ZERVIATE U.S. launch: </strong>Commercial launch of ZERVIATE (cetirizine ophthalmic solution), 0.24% in the U.S. is expected by our partner Eyevance Pharmaceuticals in H1 2020 </li> </ul> </p><p> <strong>Second Quarter 2019 and Recent Operational Highlights</strong><br /><br /><br /> <ul type="disc"> <li>The total number of prescriptions for VYZULTA in the U.S. in the second quarter of 2019 increased by 17% compared to Q1 2019<sup>1 </sup>and by 161% compared to the second quarter 2018<sup>1</sup>.</li> <li>Earlier this week we announced that we had completed enrollment of patients in our multicenter, United States (U.S.) Phase 2 clinical study evaluating NCX 470, a novel second generation NO-donating bimatoprost analog, being tested in patients with glaucoma or ocular hypertension for its ability to lower IOP.  This study is a head-to-head comparison of once-daily administration of three different doses of NCX 470 versus latanoprost, which is the most widely prescribed first-line therapy for glaucoma and ocular hypertension.  Top-line data of the study is expected early in Q4 of this year.</li> <li>In July 2019 we received a $3 ...</li></ul></p></td></tr></table><p><a href=https://www.benzinga.com/pressreleases/19/07/g14085677/nicox-second-quarter-2019-business-update-and-financial-highlights alt=Nicox: Second Quarter 2019 Business Update and Financial Highlights>Full story available on Benzinga.com</a></p> News Press Releases News Press Releases Benzinga Wed, 17 Jul 2019 05:30:00 +0000 Globe Newswire 14085677 at https://www.benzinga.com Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Pyxus International, ChinaCache International Holdings, and Zuora and Encourages Investors to Contact the Firm https://www.benzinga.com/pressreleases/19/07/g14085495/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-pyxus <link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /> <p>NEW YORK, July 16, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel &amp; Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Pyxus International, Inc., ChinaCache International Holding Ltd., and Zuora, Inc. Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.<br /></p> <p><strong>Pyxus International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PYX#NYSE" rel="nofollow">PYX</a>)</strong></p> <p>Class Period: June 7, 2018 to November 8, 2018</p> <p>Lead Plaintiff Deadline: August 6, 2019</p> <p>On November 8, 2018, the company disclosed that sales declined approximately 12% year-over-year due to the timing of shipments and the larger crop last year in South America.</p> <p>On this news, the company&#039;s share price fell $7.01, or nearly 28%, to close at $18.26 on November 8, 2018, on unusually heavy trading volume.</p> <p>On November 9, 2018, the SEC announced that the company had settled charges that it had materially misstated its financial statements filed with the SEC from at least 2011 through the second quarter of 2015 due to improper and insufficient accounting, processes, and control activities for inventory, deferred crop costs, and revenue transactions in Africa.</p> <p>On this news, the company&#039;s share price fell $2.88, or nearly 16%, to close at $15.38 on November 9, 2018, on unusually heavy trading volume.</p> <p>The complaint filed on June 7, 2019 alleges that throughout the Class Period, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company&#039;s business, operations, and prospects. Specifically, ...</p><p><a href=https://www.benzinga.com/pressreleases/19/07/g14085495/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-pyxus alt=Bragar Eagel &amp; Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Pyxus International, ChinaCache International Holdings, and Zuora and Encourages Investors to Contact the Firm>Full story available on Benzinga.com</a></p> CCIH News PYX Legal Press Releases CCIH US16950M1071 PYX News Legal Press Releases Benzinga Wed, 17 Jul 2019 01:30:00 +0000 Globe Newswire 14085495 at https://www.benzinga.com Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Anheuser-Busch, FedEx Corporation, EQT Corporation, and Sunlands Technology Group and Encourages Investors to Contact the Firm https://www.benzinga.com/pressreleases/19/07/g14085494/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-anheu <link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /> <p>NEW YORK, July 16, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel &amp; Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Anheuser-Busch InBev SA/NV, FedEx Corporation, EQT Corporation, and Sunlands Technology Group. Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.<br /></p> <p><strong>Anheuser-Busch InBev SA/NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BUD#NYSE" rel="nofollow">BUD</a>)</strong></p> <p>Class Period: March 1, 2018 to October 24, 2018</p> <p>Lead Plaintiff Deadline: August 20, 2019</p> <p>The complaint alleges that during the Class Period, defendants made materially false and misleading statements and/or failed to disclose adverse information regarding Anheuser-Busch&#039;s business, operations and prospects. Specifically, defendants failed to disclose, among other things, that cost-cutting measures the Company had put in place had run their course; the devaluation of key emerging market currencies and input cost inflation was having a material adverse effect on the Company&#039;s margins, EBITDA and profitability; Anheuser-Busch had been experiencing less than expected growth and profits in certain key markets; Anheuser-Busch was not going to be able to maintain its then current dividend and still meet its deleveraging targets; and Anheuser-Busch was at risk of having its credit ratings downgraded. As a result of this information being withheld from the market, the price of Anheuser-Busch ADSs was artificially inflated to as high as $117 per ADS during the Class Period.</p> <p>Then on October 25, 2018, the Company reported its financial results for the quarter and nine-month periods ended September 30, 2018, announcing that it had cut its dividend by 50% to "accelerate deleveraging toward our optimal capital structure of around 2x net debt to EBITDA ratio." On this news, the price of Anheuser-Busch ADSs declined approximately 9.5%, from $82.25 per ADS to $74.54 per ADS.</p> <p>For more information on the Anheuser-Busch class action go to: <a href="https://www.globenewswire.com/Tracker?data=W-QLRuElcR3kI4R3S32ySctljNG9jo051adtlDUfOrbJXuCD6hFoe6TNqb0iwNDSHGPQ_DwMNUHGI1L0R8dKjQ==" rel="nofollow" target="_blank" rel="nofollow"><u>https://bespc.com/Bud</u></a></p> <p><strong>FedEx Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE" rel="nofollow">FDX</a>)</strong></p> <p>Class Period: September 19, 2017 to November 8, 2018</p> <p>Lead Plaintiff Deadline: August 26, 2019</p> <p align="justify">The complaint filed on June 26, 2019 alleges that FedEx significantly expanded its international operations through its $4.8 billion acquisition of TNT Express N.V. (TNT), a Netherlands-based logistics company with operations concentrated in Europe. On June 27, 2017, TNTs operations were crippled by a cyberattack known ...</p><p><a href=https://www.benzinga.com/pressreleases/19/07/g14085494/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-anheu alt=Bragar Eagel &amp; Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Anheuser-Busch, FedEx Corporation, EQT Corporation, and Sunlands Technology Group and Encourages Investors to Contact the Firm>Full story available on Benzinga.com</a></p> BUD EQT FDX News STG Legal Press Releases EQT US26884L1098 FDX US31428X1063 BUD US03524A1088 STG News Legal Press Releases Benzinga Wed, 17 Jul 2019 01:30:00 +0000 Globe Newswire 14085494 at https://www.benzinga.com Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fred's, Acer Therapeutics, and Diebold Nixdorf and Intelligent Systems and Encourages Investors to Contact the Firm https://www.benzinga.com/pressreleases/19/07/g14085493/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-freds <link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /> <p>NEW YORK, July 16, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel &amp; Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Fred&#039;s, Inc., Acer Therapeutics, Inc., Diebold Nixdorf, Inc, and Intelligent Systems Corporation. Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.<br /></p> <p><strong>Fred&#039;s, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRED#NASDAQ" rel="nofollow">FRED</a>)</strong></p> <p>Lead Plaintiff Deadline: August 26, 2019</p> <p>Class Period: December 20, 2016 to June 28, 2017</p> <p>The complaint alleges that Walgreens Boots Alliance, Inc. (&#34;Walgreens&#34;), the Company and certain of their respective officers issued false and misleading statements and/or failed to disclose, among other things, the level of regulatory risk faced by the original and revised mergers pursuant to which Walgreens would acquire Rite Aid Corp. (&#34;Rite Aid&#34;) (the &#34;Original Merger&#34;).  Walgreens and Rite Aid had entered into an agreement with Fred&#39;s to sell 865 Rite Aid stores for $950 million in an all-cash transaction in order to complete the Original Merger (the &#34;Fred&#39;s Asset Purchase Agreement&#34;).</p> <p>On January 30, 2017, Rite Aid and Walgreens announced that they had entered into a new merger agreement (the &#34;Revised Merger&#34;).  On June 29, 2017, Rite Aid and Walgreens announced that they had terminated the Revised Merger.  Following the termination of the Revised Merger, Walgreens terminated the Fred&#39;s Asset Purchase Agreement.</p> <p>Defendants made materially false and misleading statements concerning the level of regulatory risk faced by the Original Merger and the Revised Merger which would ultimately cause the termination of the Fred&#39;s Asset Purchase Agreement. Specifically, Defendants made false and/or misleading statements: (i) downplaying or disputing contrary reports from journalists signaling regulatory turbulence in closing the Original Merger, as well as, the Revised Merger; and (ii) representing that inside knowledge of the FTC ...</p><p><a href=https://www.benzinga.com/pressreleases/19/07/g14085493/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-freds alt=Bragar Eagel &amp; Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fred&#039;s, Acer Therapeutics, and Diebold Nixdorf and Intelligent Systems and Encourages Investors to Contact the Firm>Full story available on Benzinga.com</a></p> ACER DBD FRED INS News Legal Press Releases INS US45816D1000 FRED US3561081007 DBD US2536511031 ACER News Legal Press Releases Benzinga Wed, 17 Jul 2019 01:30:00 +0000 Globe Newswire 14085493 at https://www.benzinga.com Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Pivotal Software, Eros International, Teva Pharmaceutical Industries, and Helius Medical Technologies and Encourages Investors to Contact the Firm https://www.benzinga.com/pressreleases/19/07/g14085492/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-pivot <link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /> <p align="left">NEW YORK, July 16, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel &amp; Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Pivotal Software, Inc., Eros International Plc, Teva Pharmaceutical Industries Ltd, and Helius Medical Technologies, Inc. Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.<br /></p> <p><strong>Pivotal Software, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVTL#NYSE" rel="nofollow">PVTL</a>)</strong></p> <p>Class Period: Securities pursuant or traceable to Pivotal&#039;s April 2018 initial public offering ("IPO") and/or securities purchased or acquired between April 24, 2019 and June 4, 2019 (the "Class Period").</p> <p>Lead Plaintiff Deadline: August 19, 2019</p> <p>The complaint filed on June 21, 2019 alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company&#39;s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Pivotal was facing major problems with its sales execution and a complex technology landscape; (ii) the foregoing headwinds resulted in deferred sales, lengthening sales cycles, and diminished growth as its customers and the industry&#39;s sentiment shifted away from Pivotal&#39;s principal products because the Company&#39;s products were outdated, inadequate, and incompatible with the industry-standard platform; and (iii) as a result, the Company&#39;s public statements were materially false and misleading at all relevant times. On June 4, 2019, post-market, Pivotal reported its financial and operating results for the first quarter of fiscal year 2020, advising investors that &#34;sales execution and a complex technology landscape impacted the quarter.&#34; Wedbush Securities analyst Daniel Ives called the quarter a &#34;train wreck&#34; and characterized the Company&#39;s operating results as &#34;disastrous,&#34; asserting that Pivotal&#39;s &#34;management team does not have a handle on the underlying issues negatively impacting its sales cycles and the activity in the field which gives ...</p><p><a href=https://www.benzinga.com/pressreleases/19/07/g14085492/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-pivot alt=Bragar Eagel &amp; Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Pivotal Software, Eros International, Teva Pharmaceutical Industries, and Helius Medical Technologies and Encourages Investors to Contact the Firm>Full story available on Benzinga.com</a></p> EROS HSDT News PVTL TEVA Legal Press Releases TEVA US8816242098 EROS HSDT PVTL News Legal Press Releases Benzinga Wed, 17 Jul 2019 01:30:00 +0000 Globe Newswire 14085492 at https://www.benzinga.com Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Heron Therapeutics, Box, Cloudera, and Mammoth Energy and Encourages Investors to Contact the Firm https://www.benzinga.com/pressreleases/19/07/g14085491/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-heron <link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /> <p>NEW YORK, July 16, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel &amp; Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Heron Therapeutics, Inc., Box, Inc, Cloudera, Inc., and Mammoth Energy Services, Inc. Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.<br /></p> <p><strong>Heron Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ" rel="nofollow">HRTX</a>)</strong></p> <p>Class Period: October 31, 2018 to April 30, 2019</p> <p>Lead Plaintiff Deadline: August 5, 2019</p> <p>The complaint filed on June 3, 2019 alleges that throughout the Class Period, defendants made materially false and misleading statements regarding the company&#039;s business, operational and compliance policies.  Specifically, the complaint alleges that defendants made false and/or misleading statements and/or failed to disclose that: (i) Heron had failed to include adequate Chemistry, Manufacturing, and Controls and non-clinical information in its NDA for HTX-011; (ii) the foregoing increased the likelihood that the FDA would not approve Heron&#039;s NDA for HTX-011; and (iii) as a result, Heron&#039;s public statements were materially false and misleading at all relevant times.</p> <p>To learn more about the Heron Therapeutics class action go to <a href="https://www.globenewswire.com/Tracker?data=W5uxDMmRZVUpOHsRRq0gnu7BtDG63HSB1uykx_Hy8Phaf4XGsJ5AqCc-0zliAklFGM1sYiGa1WQEh2JjcqITT0ofVucnAU15sNtoeYxXaqo=" rel="nofollow" target="_blank" rel="nofollow"><u>https://bespc.com/hrtx/</u></a></p> <p><strong>Box, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOX#NYSE" rel="nofollow">BOX</a>)</strong></p> <p align="justify">Class Period: November 28, 2018 to ...</p><p><a href=https://www.benzinga.com/pressreleases/19/07/g14085491/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-heron alt=Bragar Eagel &amp; Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Heron Therapeutics, Box, Cloudera, and Mammoth Energy and Encourages Investors to Contact the Firm>Full story available on Benzinga.com</a></p> BOX CLDR HRTX News TUSK Legal Press Releases CLDR US1890971088 BOX BMG799781056 HRTX TUSK News Legal Press Releases Benzinga Wed, 17 Jul 2019 01:30:00 +0000 Globe Newswire 14085491 at https://www.benzinga.com DLTa21 Announces Secured Convertible Loan https://www.benzinga.com/pressreleases/19/07/g14085446/dlta21-announces-secured-convertible-loan <link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /> <p align="center"><em>Not for distribution to U.S. news wire services or dissemination in the United States</em></p> <p align="justify">VANCOUVER, British Columbia, July 16, 2019 (GLOBE NEWSWIRE) -- DLTa21 Blockchain Corp. ("<strong>DLTa21</strong>&#34; or the "<strong>Company</strong>"), a global technology and blockchain development company, announces that it has entered into a convertible loan transaction with an international investor based in Tokyo, Japan (the &#34;<strong>Lender</strong>&#34;) pursuant to which the Lender will loan to the Company an aggregate amount of JPY 10,050,000 (the &#34;<strong>Loan</strong>&#34;). The proceeds of the Loan will be used to meet ongoing financial obligations of the Company in Japan.<br /></p> <p align="justify">The Loan has a term of three (3) months, maturing on October 10, 2019 (the "<strong>Maturity Date</strong>"), and is repayable in a single installment at maturity.  The Loan bears interest at an annual rate of 16%, payable in cash upon the earlier of maturity or conversion of the Loan. The Loan may be advanced in several tranches, with the first tranche being approximately JPY 5,000,000. The Lender shall be paid an arrangement fee equal ...</p><p><a href=https://www.benzinga.com/pressreleases/19/07/g14085446/dlta21-announces-secured-convertible-loan alt=DLTa21 Announces Secured Convertible Loan>Full story available on Benzinga.com</a></p> News Financing Press Releases News Financing Press Releases Benzinga Wed, 17 Jul 2019 00:44:48 +0000 Globe Newswire 14085446 at https://www.benzinga.com SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zuora, Inc. - ZUO https://www.benzinga.com/pressreleases/19/07/g14085421/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-zuora-inc-zuo <link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /> <p align="justify">NEW YORK, July 16, 2019 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zuora, Inc. ("Zuora" or the "Company") (NYSE: ZUO). Such investors are advised to contact Robert S. Willoughby at <a href="https://www.globenewswire.com/Tracker?data=ywDE2A1tprq1qqlCoIXsrSs7pR-GqDulrzzmzxZd5iI60S2ccOlukAUDINg4eRi5F6lRLNguGpfvJrk4HUrfRwn2IsQCQAPpssjBSi-5T2E=" rel="nofollow" target="_blank" rel="nofollow">rswilloughby@pomlaw.com</a> or 888-476-6529, ext. 9980.<br /></p> <p align="justify">The investigation concerns whether Zuora and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. </p> <p align="center"><a href="https://www.globenewswire.com/Tracker?data=5a0PTaE2vQYzTTxtNL3WM7Kon_blqj3b-Jo-cESwyuYbvanU29PxCiYmzxT_0MxMT0kY6sLJPRKGK0JmpOZEFOo61ke3fINMYGUXrhy5eWAhRsBqyFGj3DZuDq9O5VJEAy4Jm-aEPelnAg6-QEkNc8HBjskg28ZUd2NbMGaDZII=" rel="nofollow" target="_blank" rel="nofollow"><strong>[Click here for information about joining the class action]</strong></a></p> <p align="justify">In May 2017, Zuora acquired Leeyo ...</p><p><a href=https://www.benzinga.com/pressreleases/19/07/g14085421/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-zuora-inc-zuo alt=SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zuora, Inc. - ZUO>Full story available on Benzinga.com</a></p> News Legal Press Releases News Legal Press Releases Benzinga Wed, 17 Jul 2019 00:30:16 +0000 Globe Newswire 14085421 at https://www.benzinga.com